Intervention not reported
Treatment failure · treating pulmonary TB
The intervention showed no clear difference in treatment failure (moderate certainty).
1 finding from 1 review
Intervention not reported
Sputum smear or culture conversion at end of treatment · treating pulmonary TB
The intervention showed no clear difference in sputum smear or culture conversion at end of treatment (high certainty).
1 finding from 1 review
Intervention not reported
Combined endpoint of treatment failure, relapse, or death** · treating pulmonary TB
1 finding from 1 review
Intervention not reported
Serious drug related adverse events · Children aged less than 5 years
1 finding from 1 review
Relapse · adults with drug‐sensitive pulmonary tuberculosis
Moxifloxacin‐containing 4‐month ATT regimens probably leads to higher relapse compared with standard 6‐month ATT regimen (moderate certainty).
1 finding from 1 review
Serious adverse events · adults with drug‐sensitive pulmonary tuberculosis
Gatifloxacin‐containing 4‐month ATT regimens showed no clear difference in serious adverse events compared with standard 6‐month ATT regimens (moderate certainty).
1 finding from 1 review
Death from any cause · adults with drug‐sensitive pulmonary tuberculosis
Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in death from any cause compared with standard 6‐month ATT regimen (moderate certainty).
1 finding from 1 review
Serious adverse events · adults with drug‐sensitive pulmonary tuberculosis
Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in serious adverse events compared with standard 6‐month ATT regimen (moderate certainty).
1 finding from 1 review
Relapse · adults with drug‐sensitive pulmonary tuberculosis
Gatifloxacin‐containing 4‐month ATT regimens probably leads to higher relapse compared with standard 6‐month ATT regimens (moderate certainty).
1 finding from 1 review
Death from any cause · adults with drug‐sensitive pulmonary tuberculosis
Gatifloxacin‐containing 4‐month ATT regimens showed no clear difference in death from any cause compared with standard 6‐month ATT regimens (moderate certainty).
1 finding from 1 review
Intervention not reported
Virological success · antiretroviral‐naïve individuals
The intervention showed no clear difference in virological success (high certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: pyrexia · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: pyrexia (low certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: raised transaminases · antiretroviral‐naïve individuals
The intervention leads to lower severe adverse events: raised transaminases (high certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: raised alkaline phosphatase · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: raised alkaline phosphatase (low certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: raised amylase · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: raised amylase (low certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: raised triglycerides · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: raised triglycerides (low certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: neutropenia · antiretroviral‐naïve individuals
The intervention leads to lower severe adverse events: neutropenia (high certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: rash · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: rash (moderate certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: serum glutamic oxaloacetic transaminase (SGOT) · antiretroviral‐naïve individuals
1 finding from 1 review
Intervention not reported
Severe adverse events: serum glutamic‐ pyruvic transaminase (SGPT) · antiretroviral‐naïve individuals
1 finding from 1 review